{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:16:15Z","timestamp":1793373375375,"version":"4.5.0"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"11","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Alzheimer Krankheit (AD) ist eine schwere und fortschreitende\n                    neurodegenerative Erkrankung des Gehirns, die bislang mit prim\u00e4r nur\n                    symptomatisch wirksamen medikament\u00f6sen und nicht-medikament\u00f6sen Therapieformen\n                    als Standardtherapie behandelt wird. Nach der Zulassung des monoklonalen\n                    Anti-Amyloid Antik\u00f6rper durch die FDA (Food and Drug Administration) hat sich\n                    die AD-Therapie gewandelt, da es durch diese Therapie m\u00f6glich geworden ist, den\n                    biologischen Krankheitsprozess der AD zu verlangsamen. Lecanemab ist durch den\n                    Ausschuss f\u00fcr Humanarzneimittel (CHMP) der Europ\u00e4ischen Arzneimittel-Agentur\n                    (EMA) f\u00fcr die Zulassung bei Patienten mit fr\u00fcher AD unter zwei Bedingungen\n                    empfohlen worden. Erstens sollen homozygote ApoE4 Tr\u00e4ger und zweitens Patienten,\n                    die eine orale Antikoagulantien erhalten, Lecanemab nicht erhalten. In der\n                    folgenden narrativen \u00dcbersicht werden der Wirkmechanismus, die Sicherheit sowie\n                    die Nebenwirkungen von Lecanemab erl\u00e4utert. Ferner werden Risikofaktoren f\u00fcr\n                    Nebenwirkungen beschrieben. Schlie\u00dflich werden die ersten Erfahrungen mit\n                    Lecanemab aus den Vereinigten Staaten berichtet sowie die Wirksamkeit und\n                    finanzielle Aspekte diskutiert. Lecanemab f\u00fchrt zu einer vor\u00fcbergehenden\n                    Reduktion der Amyloid-\u00df Ablagerungen und zu einem Benefit, der sich in der\n                    Alltagskompetenz, Kognition und Lebensqualit\u00e4t abbilden l\u00e4sst und durch seine\n                    nachweisbare biologisch-klinische nachweisbare Wirksamkeit als ein Durchbruch\n                    der AD-Therapie bezeichnet werden kann.<\/jats:p>","DOI":"10.1055\/a-2681-4558","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:00:41Z","timestamp":1759791641000},"page":"453-460","source":"Crossref","is-referenced-by-count":4,"title":["Krankheitsmodifizierende Therapie mit Lecanemab bei fr\u00fcher\n                    Alzheimer-Demenz"],"prefix":"10.1055","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-9594","authenticated-orcid":false,"given":"Niels","family":"Hansen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie,\n                    Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), G\u00f6ttingen,\n                    Germany"},{"name":"Biomedizinisches Institut (iBiMED), Universit\u00e4t von Aveiro, Aveiro,\n                    Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"ref1","first-page":"1598","article-title":"Alzheimer\u2019s disease facts and figures","volume":"4","author":"Alzheimer\u2019s Association","year":"2023","journal-title":"Alzheimer\u2019s Dementia"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","article-title":"The worldwide costs of dementia in 2019","volume":"19","author":"A Wimo","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/alz.12730","article-title":"The impacts of health insurance and resource on the burden of Alzheimer\u2019s\n                    disease and related dementias in the world population","volume":"19","author":"J T Wang","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ibra.12181","article-title":"Global, regional, and national burdens of Alzheimer\u2019s disease and other forms of\n                    dementia in the elderly population from 1999 to 2019: A trend analysis based on\n                    the Global Burden of Disease Study 2019","volume":"10","author":"M Su","year":"2024","journal-title":"Ibrain"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s\n                    Association Workgroup","volume":"20","author":"C R Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14397.","article-title":"Plasma p-tau immunoassays in clinical research for Alzheimer\u2019s disease","author":"C E Teunissen","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"C H van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a\n                    Regional Medical Center","volume":"11","author":"LB E Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"J Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"102620","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer\u2019s disease:\n                    A systematic review and meta-analysis","volume":"104","author":"N Arroyo-Pacheco","year":"2024","journal-title":"Ageing Res Rev"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","article-title":"Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils","volume":"30","author":"B O\u2019Nuallain","year":"2010","journal-title":"J Neurosci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early\n                    Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"C J Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer's disease","volume":"144","author":"S S Plotkin","year":"2020","journal-title":"Neurobiol Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e2314450121","DOI":"10.1073\/pnas.2314450121","article-title":"Lecanemab blocks the effects of the Abeta\/fibrinogen complex on blood clots and\n                    synapse toxicity in organotypic culture","volume":"121","author":"P K Singh","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40120-023-00460-1","article-title":"Estimated Societal Value of Lecanemab in Patients with Early Alzheimer\u2019s Disease\n                    Using Simulation Modeling","volume":"12","author":"A A Tahami Monfared","year":"2023","journal-title":"Neurol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind\n                    Phase 3 Trial in Early Alzheimer\u2019s Disease","volume":"10","author":"S Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s\n                    disease","volume":"16","author":"L S Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","article-title":"A Quarter Century of APOE and Alzheimer\u2019s Disease: Progress to Date and the Path\n                    Forward","volume":"101","author":"M E Belloy","year":"2019","journal-title":"Neuron"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12975-013-0288-8","article-title":"Thrombin-induced cerebral hemorrhage: role of protease-activated receptor-1","volume":"5","author":"Y Cheng","year":"2014","journal-title":"Transl Stroke Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on A\u03b2 immunotherapy induced ARIA","volume":"16","author":"K E Foley","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A\n                    Meta-analysis","volume":"74","author":"S C Neu","year":"2017","journal-title":"JAMA Neurol"},{"key":"ref24","volume-title":"2024 In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ,\n                    editors. Lecanemab Therapy and APOE Genotype. Medical Genetics Summaries\n                    [Internet]","author":"M Kane","year":"2012"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v15i1.5787.","article-title":"Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer\u2019s\n                    Disease","volume":"15","author":"C H Yoon","year":"2024","journal-title":"Innov Pharm"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1212\/WNL.0000000000012778","article-title":"Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related\n                    Inflammation: A Multicenter Prospective Longitudinal Cohort Study","volume":"97","author":"L Antolini","year":"2021","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(24)02510-8","article-title":"Amyloid-lowering treatment in Alzheimer\u2019s disease","volume":"404","author":"F Jessen","year":"2024","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1212\/WNL.0000000000207505","article-title":"Lecanemab: Looking Before We Leap","volume":"101","author":"J F Burke","year":"2023","journal-title":"Neurology"},{"key":"ref30","first-page":"17","article-title":"Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities?\n                    A Cross-Sectional Study","author":"K Ohashi","year":"2024","journal-title":"Health Serv Insights"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e12500","DOI":"10.1002\/trc2.12500","article-title":"Perspectives on the clinical use of anti-amyloid therapy for the treatment of\n                    Alzheimer\u2019s disease: Insights from the fields of cancer, rheumatology, and\n                    neurology","volume":"10","author":"G A Jicha","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3233\/JAD-230633","article-title":"Analysis of Costs for Imaging-Assisted Pharmaceutical Intervention in\n                    Alzheimer\u2019s Disease with Lecanemab: Snapshot of the First 3 Years","volume":"96","author":"J Perron","year":"2023","journal-title":"J Alzheimers Dis"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2681-4558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T23:44:18Z","timestamp":1762472658000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2681-4558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2681-4558","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}